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COVID-19: Convalescent plasma as a 
potential therapy
To the Editor: SARS-CoV-2, the cause of COVID-19, has posed 
a significant threat to global health. No specific treatment or 
effective prophylaxis has been established, and care of severely 
ill patients is largely supportive, with poor outcomes in those 
requiring ICU admission. Experimental therapies include antiviral 
agents such as remdesivir,[1] lopinavir/ritonavir[2] and favipiravir,[3] 
hydroxychloroquine/chloroquine,[4] interleukin-6 inhibitors such 
as tocilizumab,[5] siltuximab[6] and sarilumab,[7] and COVID-19 
convalescent plasma (CCP).[8]
CCP has been included in the treatment guidelines for severe 
COVID-19 in China,[9] and the Food and Drug Administration has 
recently approved its use for critically ill COVID-19 patients in the 
context of clinical trials and through the expanded access programme 
in the USA.[10] Interest has been expressed in the use of CCP for 
COVID-19 treatment in South Africa (SA).
CCP refers to plasma collected from donors who have recovered 
from COVID-19 and are likely to have produced neutralising 
antibodies to SARS-CoV-2. It is hypothesised that the infusion of 
plasma with virus-specific antibodies confers immediate transfer 
of passive immunity to the recipient and may improve the clinical 
course and outcomes by accelerating viral clearance and antibody-
dependent cell-mediated cytotoxicity of infected cells.[11]
The use of convalescent plasma (CP) as passive immunisation to 
treat viral infections is not novel.[12] Early administration of CP has 
proved successful in reducing mortality from severe influenza[13,14] 
as well as the related epidemic coronavirus severe acute respiratory 
syndrome (SARS)-CoV,[15] and has been used successfully in 
Middle East respiratory syndrome (MERS)-CoV[16] and Ebola virus 
disease.[17] Studies using CP in various viral infections have shown 
improvement of both laboratory and clinical parameters,[13,18-22] 
including a reduction in the hyperinflammatory cytokine response, 
which appears to be a critical driver of morbidity and mortality in 
COVID-19.[23,24] Where CP was used to treat SARS-CoV infections, 
the absolute risk reduction in mortality ranged between 7% and 
23%,[25-30] and CP was associated with earlier discharge from 
hospital. [15,26,27,30] It is because of the positive results of these trials, 
in addition to the lack of successful treatment options available at 
present, that the use of CCP has been considered in the current 
SARS-CoV-2 pandemic.
Studies of the use of CCP from China have shown potential 
benefit, including improved survival,[31,32] reductions in viral load[31-33] 
and improved radiological features.[31,32,34] These studies have various 
limitiations, including small numbers of patients, lack of blinded, 
randomised or placebo-controlled trials, and patients receiving a 
multitude of different therapies. One study involving 6 critically 
ill patients[33] found that although all the patients became SARS-
CoV-2 RNA-negative within 3 days of CCP infusion, 5 eventually 
died. Consequently, before CCP can be considered as an effective 
treatment option, testing of its safety and efficacy in large randomised 
controlled trials has been recommended,[8,35] and trials are underway 
in the USA, the UK, Canada, Brazil and Italy, as well as several other 
European countries. Early safety[36] and treatment[37] outcomes appear 
encouraging, with non-ventilated patients benefiting more than those 
requiring ventilation. Historical use of CP has shown that it is most 
effective when used as prophylaxis or early in treatment, and these 
findings need to be established for CCP.
There are unique challenges around the collection of CP during 
a pandemic. These include biological, such as ensuring that donors 
are clinically and virally free of SARS-CoV-2 and with a sufficient 
antibody titre to be therapeutically effective; logistical, such as 
travel/movement bans; legal, such as donor consent and eligibility, 
and regulatory requirements for administration of CP in a clinical 
trial; and scientific, such as limited commercial availability of 
validated assays for antibody titre testing. National blood services 
are uniquely positioned to address and manage these challenges, 
as they are likely to already have appropriate infrastructure and 
networks to support the rapid collection, testing and storage of 
blood products such as CP. While studies have shown that CP is 
safe, the theoretical risks of receiving any blood products need to 
be considered, including transfusion-transmissible infections and 
transfusion-related acute lung injury (TRALI), specifically in the 
setting of a respiratory virus. These risks need to be mitigated by 
ensuring that CCP donors comply with all standard eligibility and 
testing criteria established for regular blood donations; excluding 
parous female donors to reduce the incidence of TRALI; and using 
pathogen reduction to target transfusion-transmissible infections. 
Furthermore, there is a theoretical risk that other non-anti-SARS-
CoV-2-neutralising antibodies may cause antibody-dependent 
enhancement of infection. Internationally, the willingness of 
recovered patients to donate CCP has ensured a sustainable CCP 
supply.
With no proven effective therapy against COVID-19 available in 
SA, and in the context of limited resources to provide care to patients 
with critical illness, it is a research priority to evaluate potential 
therapeutic interventions in an SA population. An effective vaccine 
is required for sustained population immunity, but development, 
manufacture and scale-up are likely to be several months away. It 
is therefore appealing to consider CCP, which may offer immediate 
passive immunity, and production of which could be rapidly scaled 
to be widely available throughout the country in a matter of weeks. 
However, we would caution that given the current paucity of data 
and potential risks and complexities, before the use of CCP can be 
recommended, randomised controlled trials are needed to establish 
therapeutic efficacy and safe use for COVID-19 disease.
Conflicts of interest. VJL is non-executive director of the Board of the 
Western Cape Blood Service.
Karin van den Berg
Translational Research, Medical Division, South African National 
Blood Service, Roodepoort, South Africa; and Division of Clinical 
Haematology, Department of Medicine, Faculty of Health Sciences, 
University of Cape Town, South Africa
karin.vandenberg@sanbs.org.za
Marion Vermeulen
Operations Testing, Operations Division, South African National 
Blood Service, Roodepoort, South Africa
Tanya Nadia Glatt
Director, Cellular Therapy Laboratory, South African National Blood 
Service, Roodepoort, South Africa
Sean Wasserman
Division of Infectious Diseases and HIV Medicine, Department of 
Medicine, Faculty of Health Sciences, University of Cape Town, South 
Africa; and Wellcome Centre for Infectious Diseases Research in 
Africa, Institute of Infectious Disease and Molecular Medicine, Faculty 
of Health Sciences, University of Cape Town, South Africa
This open-access article is distributed under 
Creative Commons licence CC-BY-NC 4.0.
CORRESPONDENCE
563       July 2020, Vol. 110, No. 7
Claire L Barrett
School of Clinical Medicine, Faculty of Health Sciences, University of 
the Free State, Bloemfontein, South Africa
Jonny Peter
Division of Allergy and Clinical Immunology, Department of 
Medicine, Faculty of Health Sciences, University of Cape Town, South 
Africa; and Allergy and Immunology Unit, University of Cape Town 
Lung Institute, South Africa
David Brittain
Alberts Cellular Therapy, Netcare Pretoria East Hospital, South Africa
Vernon J Louw
Division of Clinical Haematology, Department of Medicine, Faculty of 
Health Sciences, University of Cape Town, South Africa
1. Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. 
N Engl J Med 2020 (epub 10 April 2020). https://doi.org/10.1056/NEJMoa2007016 
2. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. 
N Engl J Med 2020;382(21):e68. https://doi.org/10.1056/NEJMc2008043
3. Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: An open-
label control study. Engineering (Beijing) 2020 (epub 18 March 2020). https://doi.org/10.1016/j.
eng.2020.03.007
4. Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available 
weapons to fight COVID-19. Int J Antimicrob Agents 2020;55(4):105932. https://doi.org/10.1016/j.
ijantimicag.2020.105932
5. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl 
Acad Sci U S A 2020;117(20):10970-10975. https://doi.org/10.1073/pnas.2005615117
6. ClinicalTrials.gov. An observational study of the use of siltuximab (SYLVANT) in patients diagnosed 
with COVID-19 infection who have developed serious respiratory complications (SISCO). 
ClinicalTrials.gov Identifier: NCT04322188. 26 March 2020. https://clinicaltrials.gov/ct2/show/
NCT04322188 (accessed 10 May 2020).
7. ClinicalTrials.gov. Sarilumab COVID-19. ClinicalTrials.gov Identifier: NCT04327388. 31 March 2020. 
https://clinicaltrials.gov/ct2/show/NCT04327388 (accessed 10 May 2020).
8. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect 
Dis 2020;20(4):398-400. https://doi.org/10.1016/S1473-3099(20)30141-9
9. Treatment guide of COVID-19 pneumonia caused by new coronavirus infection. 7th ed. 3 March 
2020. Translated to English. http://www.gov.cn/zhengce/zhengceku/2020-03/04/content_5486705.
htm (accessed 10 May 2020).
10. Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ 
2020;368:m1256. https://doi.org/10.1136/bmj.m1256
11. Rojas M, Rodriguez Y, Monsalve DM, et al. Convalescent plasma in Covid-19: Possible mechanisms of 
action. Autoimmun Rev 2020;19(7):102554. https://doi.org/10.1016/j.autrev.2020.102554
12. Marano G, Vaglio S, Pupella S, et al. Convalescent plasma: New evidence for an old therapeutic tool? 
Blood Transfus 2016;14(2):152-157. https://doi.org/10.2450/2015.0131-15
13. Hung IF, To KK, Lee CK, et al. Convalescent plasma treatment reduced mortality in patients with 
severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011;52(4):447-456. https://
doi.org/10.1093/cid/ciq106
14. Hung IFN, To KKW, Lee CK, et al. Hyperimmune IV immunoglobulin treatment: A multicenter 
double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. 
Chest 2013;144(2):464-473. https://doi.org/10.1378/chest.12-2907
15. Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. 
Eur J Clin Microbiol Infect Dis 2005;24(1):44-46. https://doi.org/10.1007/s10096-004-1271-9
16. Ko JH, Seok H, Cho SY, et al. Challenges of convalescent plasma infusion therapy in Middle East 
respiratory coronavirus infection: A single centre experience. Antivir Ther 2018;23(7):617-622. https://
doi.org/10.3851/IMP3243
17. Van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of convalescent plasma for Ebola virus 
disease in Guinea. N Engl J Med 2016;374(1):33-42. https://doi.org/10.1056/NEJMoa1511812
18. Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest 
2020;130(4):1545-1548. https://doi.org/10.1172/JCI138003
19. Casadevall A, Scharff MD. Return to the past: The case for antibody-based therapies in infectious 
diseases. Clin Infect Dis 1995;21(1):150-161. https://doi.org/10.1093/clinids/21.1.150
20. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev 
Microbiol 2004;2(9):695-703. https://doi.org/10.1038/nrmicro974
21. Sahr F, Ansumana R, Massaquoi TA, et al. Evaluation of convalescent whole blood for treating 
Ebola virus disease in Freetown, Sierra Leone. J Infect 2017;74(3):302-309. https://doi.org/10.1016/j.
jinf.2016.11.009
22. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. 
N Engl J Med 2007;357(14):1450-1451. https://doi.org/10.1056/NEJMc070359
23. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death 
in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020 (epub 
13 March 2020). https://doi.org/10.1001/jamainternmed.2020.0994
24. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in 
Wuhan, China. Lancet 2020;395(10223):497-506. https://doi.org/10.1016/S0140-6736(20)30183-5
25. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and 
hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral 
etiology: A systematic review and exploratory meta-analysis. J Infect Dis 2015;211(1):80-90. https://
doi.org/10.1093/infdis/jiu396
26. Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing 
high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004;10(7):676-678. 
https://doi.org/10.1111/j.1469-0691.2004.00956.x
27. Zhou XZ, Zhao M, Wang FS, et al. [Epidemiologic features, clinical diagnosis and therapy of first 
cluster of patients with severe acute respiratory syndrome in Beijing area]. Zhonghua Yi Xue Za Zhi 
2003;83(12):1018-1022. 
28. Nie QH, Luo XD, Hui WL. Advances in clinical diagnosis and treatment of severe acute respiratory 
syndrome. World J Gastroenterol 2003;9(6):1139-1143. https://doi.org/10.3748/wjg.v9.i6.1139
29. Wong VW, Dai D, Wu AK, Sung JJ. Treatment of severe acute respiratory syndrome with convalescent 
plasma. Hong Kong Med J 2003;9(3):199-201.
30. Yeh KM, Chiueh TS, Siu LK, et al. Experience of using convalescent plasma for severe acute respiratory 
syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother 2005;56(5):919-
922. https://doi.org/10.1093/jac/dki346
31. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. 
Proc Natl Acad Sci U S A 2020;117(17):9490‐9496. https://doi.org/10.1073/pnas.2004168117
32. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent 
plasma. JAMA 2020;323(16):1582-1589. https://doi.org/10.1001/jama.2020.4783
33. Zeng QL, Yu ZJ, Gou JJ, et al. Effect of convalescent plasma therapy on viral shedding and survival in 
COVID-19 patients. J Infect Dis 2020;jiaa228. https://doi.org/10.1093/infdis/jiaa228
34. Xinhua. China puts 245 COVID-19 patients on convalescent plasma therapy. http://www.xinhuanet.
com/english/2020-02/28/c_138828177.htm (accessed 23 April 2020).
35. Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and 
treatment of COVID-19. J Clin Invest 2020;130(6):2757‐2765. https://doi.org/10.1172/JCI138745
36. Joyner M, Scott Wright R, Fairweather D, et al. Early safety indicators of COVID-19 convalescent 
plasma in 5,000 patients. Medrxiv, 14 May 2020. https://doi.org/10.1101/2020.05.12.20099879 
(accessed 3 June 2020).
37. Liu STH, Lin H-M, Baine I, et al. Convalescent plasma treatment of severe COVID-19: A matched 
control study. Medrxiv, 22 May 2020. https://doi.org/10.1101/2020.05.20.20102236 (accessed 3 June 
2020).
S Afr Med J 2020;110(7):562-563. https://doi.org/10.7196/SAMJ.2020.v110i7.14983
